GlassScriptPhysician profile
Kari H Fay
NPI 1023236304
$10,748.98
in general payments reported to CMS, 2019-2025
21 companies · $3,428 in 2025
The $3,428 reported for 2025 was more than what 96% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60.60 · 2020: $191 · 2021: $309 · 2022: $358 · 2023: $6,128 · 2024: $274 · 2025: $3,428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $8,647 · Food and Beverage: $1,183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $8,646.80 |
| Food and Beverage | $1,183.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $8,903.43 | 2022-2025 | Nexplanon |
| Abbvie INC. | $657.31 | 2020-2025 | |
| Allergan, INC. | $324.53 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $206.42 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $131.96 | 2023-2025 | Gemtesa, Myfembree |
| Therapeuticsmd, INC. | $68.62 | 2020-2022 | |
| Exeltis, USA INC. | $64.79 | 2023-2025 | Slynd |
| Myovant Sciences INC. | $58.51 | 2021-2022 | |
| Biogen, INC. | $51.73 | 2024-2025 | Zurzuvae |
| Shield Therapeutics INC | $44.55 | 2023-2025 | Accrufer |
| Pfizer INC. | $42.94 | 2025 | |
| Astellas Pharma US INC | $36.28 | 2023-2025 | Veozah |
| Avion Pharmaceuticals | $29.42 | 2020 | |
| Coopersurgical, INC. | $27.10 | 2021 | |
| Axonics, INC. | $20.03 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $18.94 | 2024 | Femring, Intrarosa |
| Agile Therapeutics, INC. | $18.07 | 2022 | |
| Urovant Sciences INC | $15.76 | 2022 | |
| Aspira Women'S Health INC | $14.79 | 2020 | |
| Mylan Pharmaceuticals INC. | $13.80 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kari Fay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.